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Abstract
The glioma-oncogenic proteins, or GLI proteins play a vital role in the body during
development and in diseases. However, not much is known about GLI protein’s additional roles
in the body, specifically GLI3. Through previous works in the Elsawa laboratory findings
showed a novel role of GLI3 impacting the inflammatory response. Inflammation has potential to
affect many pathways in the body including nociception and nociceptive pain. Therefore, the
goal of this study was to elucidate the role of GLI3 in inflammatory pain. C57BL/6J adult mice
were tested to observe putative knockout of GLI3 (cre-induced mice) in comparison to mice with
GLI3 (non cre-induced mice). Inflammatory models were created using Complete Freund’s
Adjuvant (CFA) that when injected in the paw promoted an increase in paw width or paw edema.
To study the thermal nociceptive response, or paw withdrawal, a Hargreaves Plantar tests was
performed. Similarly, to study paw withdrawal in response to mechanical nociception a Von
Frey Filament test was performed. Statistical tests compared mouse baseline measurement in
paw widths and behavioral tests pre-injection, and 2- and 10-days post-injection. There appeared
to be a significant difference in paw edema post-injection in cre-induced mice in comparison to
non cre-induced mice. Thus, suggesting there was a difference in the acute inflammatory
response. In thermal nociceptive studies there was a significant difference in baseline responses
between cre-induced mice and non cre-induced mice. Alternatively, there was no significant
difference in response post-injection. This suggested that GLI3 could affect thermal response but
not thermal hypersensitivity. In comparison to the mechanical nociceptive response, there was no
significant difference between cre-induced and non cre-induced mice pre- or post-injection.
Overall, GLI3 seems to play a role in acute inflammation or innate immune responses.
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CHAPTER 1: ELUCIDATING THE ROLE OF GLI3 IN INFLAMMATORY
PAIN
INTRODUCTION
Nociceptive Pain
Nociception is a vital response that prevents a stimulus from causing damage to the body
(Nociception, 2020). Nociception was first described in 1906 by Charles Sherrington, who
observed muscle reflexes occurring in response to a “nocous stimulus” that threatened bodily
harm (Sherrington, 1906). One hundred years later, nociception is formally defined as the
process of encoding, or processing, noxious stimuli (Dubin & Patapoutian, 2010). Nociceptive
responses can be elicited by thermal, mechanical, cold, or chemical stimuli (Smith, 2018; Wood,
2008). For example, a thermal stimulus, such as contact with a hot stove, can cause damage or
burns. However, the nociceptive response causes the body to pull away, thus minimizing harm
(Nociception, 2020). Mouse models are a powerful tool for approaching nociception because of
similarities in nociceptive response (Barrot, 2012). The pathway of nociception is the conserved
between mice and humans through the peripheral nervous system (Barrot, 2012).
The interpretation and activation of nociceptive pain depends on a vast network of
nociceptors: neurons with free nerve endings
that receive and interpret noxious stimuli
(Colloca et al., 2017; Nociception, 2020).
These excitatory neurons extend throughout
the body, branching from the peripheral
nervous system into the skin, muscle,

Figure 1. The nociceptor structure mirrors all
neurons in the body with an axon, cell body, and
presynaptic terminal. (Nociception, 2020.).

tendons, and joints (Colloca et al., 2017;
Dubin & Patapoutian, 2010). While each neuron
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has an axon, cell body, and presynaptic terminal in common, modifications to the basic neuronal
structure generate diverse types of nociceptors (Dubin & Patapoutian, 2010) (Figure 1.). The
differences in structure allow for specialization or unique interpretation of nociceptive stimuli
(Dubin & Patapoutian, 2010).
Nociceptor Variation and Function
Nociceptors are divided into two main categories, depending on fiber type: alpha delta
fibers (A𝛿) or C-fibers (Stahl, 2021) (Table 1; Figure 2.). A𝛿 fibers have a myelinated axon
with a medium diameter (Ossipov, 2012). Myelination enables fibers to conduct action potentials
and act as the first response to nociceptive pain (Dubin & Patapoutian, 2010). Two distinct
subcategories of alpha fibers - Type I A𝛿 and Type II A𝛿 - are distinguished by their ability to
process or tolerate specific noxious stimuli (Stahl, 2021.; Nociception, 2020). Type I A𝛿 fibers
are responsive to poignant mechanical stimuli and a high degree of heat (Ossipov, 2012).Type II
A𝛿 fibers are resistant to mechanical stimuli but susceptible to thermal stimulation (Dubin &
Patapoutian, 2010; Nociception, 2020).
C-fibers differ from A𝛿 fibers due to their unmyelinated axon, generating action
potentials of low conductivity and a slower nociceptive response (Stahl, 2021). C-fibers thus act
as a secondary response to pain, creating a dull and burning sensation (Dubin & Patapoutian,
2010). Like alpha fibers, C-fibers are polymodal (i.e., respond to numerous stimuli) and are
divided into two types: mechanical and heat-sensitive (C-MHs) and mechanically insensitive Cfibers (C-MIAs) (Dubin & Patapoutian, 2010; Nociception, 2020). The majority of C-fibers
belong to the C-MH category and respond to multiple noxious stimuli (Wooten et al., 2014).
Different subtypes of C-MHs can either conduct heat stimuli quickly or act as a buffer to slow

2

their conduction (Wooten et al., 2014). C-MIAs are resilient to mechanical stimuli but respond to
specific molecules, such as histamines and capsaicin (Wooten et al., 2014).
Nociceptive Fiber

A𝛿 fibers

Characteristics

Response to Stimuli

● Myelinated axons
● Quick response time
● High level of conductivity
● Medium Diameter

C-fibers

● Unmyelinated axons
● Lagging in response time
● Smaller diameter

● Interprets mechanical
stimuli (Type I)
● Interprets thermal stimuli
(Type II)
● Generates a slow burning
sensation
● Responds to heat and
chemical stimuli (C-MHs
and C-MIAs)

Table 1. Nociceptor fiber functions and characteristics
Like their structure, the location of nociceptors plays a critical role in noxious stimuli
perception (Nociception, 2020). One area of the body can localize numerous nociceptors that
alter in function. For example, A𝛿 and C-fibers are distributed throughout the skin, but some are
more specialized than others (Figure 2). Such as Type I A𝛿 -fibers that interpret mechanical
stimuli in specific areas of the skin with hair and oil (Nociception, 2020). Whereas additional
A𝛿-fibers in the skin are not specialized. How the nociceptor is placed in relation to a body part
is also critical for nociceptor interpretation. Despite their variation in function, location, and
structure, all nociceptors follow the same path for interpretation.
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Nociception Response and Pathway
The body’s interpretation of
nociceptive pain differs from a general
pain response (Colloca et al., 2017; Smith,
2018). General pain responses elicit a
reaction in the peripheral and the central
nervous systems, creating an emotional
response to the damaging stimuli (Barrot,
2012). The nociceptive response differs
from the pain response as it encodes
painful periphery or somatosensory stimuli that do
Figure 2. C-fibers vs. Alpha fibers pathways
during activation (Dubin & Patapoutian, 2010)

not elicit an emotional response (Colloca et al.,
2017; Smith, 2018).

When a noxious stimulus activates free nerve endings of nociceptors, a signal first travels
to the dorsal sensory fibers (Dubin & Patapoutian, 2010; Hasudungan, 2013). The peripheral
dorsal fibers send the signal to the dorsal horn of the spinal cord, prompting excitatory afferent
fibers such as alpha fibers to release the signal's neurotransmitters (such as glutamates or
substance P) into the dorsal horn (Dubin & Patapoutian, 2010; Hasudungan, 2013). These signals
are routed to the brain via secondary order neurons (Hasudungan, 2013). A common secondary
neuronal route is the spinothalamic pathway which connects the signal to the thalamus
(Hasudungan, 2013). Finally, third-order neurons send the signal to the somatosensory cortex for
interpretation (Hasudungan, 2013). The interpretation then allows an individual to recognize and
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take action against the stimulus to
prevent further harm to the body
(Hasudungan, 2013) (Figure 3).
Inflammation
A prominent variable
affecting nociception is
inflammation, which is the body’s
response to foreign invaders or injury
(Lacy & Stow, 2011; Nociception,
2020). For example, the body reacts
with inflammation in response to an
Figure 3. Pathway of nociception and interpretation in the
human body

invasive bacteria’s
lipopolysaccharide coating (Pahwa et

al., 2021). Recruitment to the site of as rheumatoid arthritis (Chen et al., 2018). invasion or
injury leads to several reactions depending on the type of inflammation: acute or chronic (Lacy
& Stow, 2011). Acute inflammation occurs in response to trauma or noxious stimuli and causes a
rapid onset of inflammation, such as a splinter (Pahwa et al., 2021). Chronic inflammation results
from a persistent invader, chronic illness, or extreme injury and accumulates more damage to a
body than acute pain (Pahwa et al., 2021). The effects of acute inflammation last for a few days
to weeks, whereas chronic inflammation impacts an individual from months to years (Pahwa et
al., 2021). During chronic inflammation the immune system fighting an invader can go into
overdrive, attacking not an invader but the body itself, leading to tissue death or chronic
inflammatory conditions such as rheumatoid arthritis (Chen et al., 2018).
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While inflammatory response differs depending on the causative agent, the process
follows similar progression (Pahwa et al., 2021). The first response in the inflammatory pathway
is recognizing an unknown invader and determining how to respond (Chen et al., 2018). For
example, recognition occurs via danger-associated molecular patterns (DAMPS), which activates
pattern recognition receptors (PRRs), such as Toll-like receptors (Chen et al., 2018). This
recognition process kickstarts immune cells – such as macrophages and dendrites- to recruit
signaling cells to the area of inflammation (Pahwa et al., 2021). These additional cells aid in
engulfing the perceived foreign invader (Pahwa et al., 2021). Various innate immune cells then
stimulate pathways to promote chemokine and cytokine production (Pahwa et al., 2021).
Chemokines and cytokines such as IL-6 and TNF-α act to promote an inflammatory response,
while cytokines such as IL-10 suppress inflammation, thus promoting the recruitment of more
immune cells to the area of inflammation (Pahwa et al., 2021). The now inflamed tissue leads to
an over-sensitization to non-painful stimuli, or allodynia (Su et al., 2014). In addition, damage
also causes hyperalgesia or an exaggerated pain response to acute trauma (McAllister, 2013; Su
et al., 2014).
Regardless of what elicits an immune response, each immune cell will release proteins to
instigate an inflammatory response (Su et al., 2014). The proteins and immune cells released,
such as cytokines, have a profound effect on cells in the body, including nociceptors (Chen et al.,
2018). Immune mediators- such as mast cells- interact with nociceptor receptors to alter the
pathway and signaling of nociceptive pain (Pinho-Ribeiro et al., 2017) (Figure 4.). For example,
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macrophages produce
pro-inflammatory cytokine IL-6,
which interacts with the
nociceptor free nerve endings
(Pinho-Ribeiro et al., 2017)
The activation of immune
mediators modifies ion channels
Figure 4. Interaction of immune cell mediators with nociceptor
neurons (Pinho-Ribeiro et al., 2017)

of nociceptors to activate kinases
(Su et al., 2014). These kinases

then phosphorylate nociceptor receptors and modify additional ion channels, causing changes in
action potential frequency (Pinho-Ribeiro et al., 2017; Su et al., 2014). Altered action potentials
lead to an increase in neuron excitability and nociceptor sensitivity (Chen et al., 2018). As
neuron excitability increases, so does the peptide neurotransmitter release in the dorsal root
ganglia (Su et al., 2014). The frequent pain response generates nociceptor sensitivity to a noxious
stimulus or central sensitization (Chen et al., 2018; McAllister, 2013; Pinho-Ribeiro et al., 2017).
While many immune and inflammatory pathways are well understood, the molecular triggers for
responses need further study. Previous research has established the importance of GLI proteins in
inflammation, although their exact role is not yet fully understood (Matissek et al., 2021).
Function of the GLI Family
The glioma-associated oncogene family (GLI) is a group of transcription factor proteins
that are related to the group GLI genes (Hui & Angers, 2011). The GLI family members – GLI1,
GLI2, and GLI3- have similarities but are distinguished by unique biochemical regions (Hui &
Angers, 2011; Matissek & Elsawa, 2020). Each GLI family member contains a five zinc finger
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binding domain, transactivation domain, and SUFU site for Hedgehog signaling (Hui & Angers,
2011; Matissek & Elsawa, 2020). However, GLI2 and GLI3 differ from GLI1, as their
biochemical structure includes a repressor domain (Matissek & Elsawa, 2020). In addition, GLI1
and GLI2 each have unique isoforms or structural variations of the GLI protein (Hui & Angers,
2011). GLI3 isoforms have yet to be explored in the human body for a difference in structure and
function (Matissek & Elsawa, 2020).
The function of the five zinc finger binding domain is critical to assist in DNA binding
2011). The SUFU site is crucial in GLI's role with Hedgehog (Hh) signaling, or a process critical
for cell development (Matissek & Elsawa, 2020). The transactivation domain promotes protein
expression by positively encouraging transcription (Næs et al., 2020). Alternatively, the
repressor domain suppresses the promotion of transcriptional activity (Matissek & Elsawa,
2020). As shown in Figure 5, the transactivation domain in GLI3 is recognized as GLI3-FL,
while the repressor domain is recognized as GLI3-R (Matissek & Elsawa, 2020

Figure 5. GLI3 biochemical domains include a repressor domain (red), SUFU site (purple), zinc finger binding
domain (blue), and a transactivation domain(green) (Matissek & Elsawa, 2020).

The GLI family proteins control all forms of Hedgehog (Hh) signaling pathways, which
is vital for physical development (Matissek & Elsawa, 2020). Hh signaling activation occurs by
binding specific cells to inactivate transmembrane protein Patched (Ptc/Ptch) (Hui & Angers,
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2011; Matissek et al., 2021). Patched then binds ligand Smoothened (SMO) to activate Hh
signaling and expression of Hh genes (Matissek & Elsawa, 2020). When SMO is inactive, the
SUFU region on GLI prevents the activation of GLI transcription factors (Matissek & Elsawa,
2020). Hh signaling, therefore, indirectly controls GLI by balancing the activation and repression
of GLI expression (Hui & Angers, 2011). The GLI proteins in turn are vital to activate or repress
Hh signaling in the embryo and fetal development (Hui & Angers, 2011).
Beyond Hh signaling, GLI protein is responsible for the activation and repression of
several immune modulators (Niewiadomski et al., 2019). For example, phosphorylation of GLI
proteins can induce GLI3-R formation (Niewiadomski et al., 2019). Modifications to GLI can
also lead to detrimental mutations during development generating diseases such as Greig
cephalopolysyndactyly syndrome (GCPS). GCPS ultimately causes fetal limb and craniofacial
maldevelopment (Matissek & Elsawa, 2020). GLI modification can also contribute to cancerous
mutations and tumors (Matissek & Elsawa, 2020). Moreover, recent research involving GLI3
suggests it may have a novel role in inflammation (Matissek & Elsawa, 2020).
Function of GLI3: Immunity and Inflammation
GLI3 plays a central role in cancer and Hh signaling as well as immune regulation.
Hager-Theodorides et al (2005) first described GLI3’s function promoting regulation of T-cell
factors during the development of fetal thymocytes (Hager-Theodorides et al., 2005). They
subsequently described additional function of GLI3 in the thymus stroma (Hager-Theodorides et
al., 2009). The thymus stroma contains a variety of immune cells such as thymus epithelial cells,
B-cells, dendritic cells, etc. (Han & Zúñiga-Pflücker, 2021). The thymus stroma also promotes
thymocyte development and controls thymus epithelial function through transcriptional
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regulation, which appears to be mediated by GLI3 (Hager-Theodorides et al., 2009; Han &
Zúñiga-Pflücker, 2021).
Recent studies show a novel pathway of GLI3 activation, which may result in the
promotion of inflammation (Matissek et al., 2021). The Elsawa laboratory explored the role of
GLI3 by using wild type and GLI3 knockout mice. Oxazolin was applied to the mice to induce
atopic dermatitis or inflammation, to observe any differences in knockout mice (Matissek et al.,
2021). The atopic dermatitis with the addition of ligand monophosphoryl lipid A (MPLA)
activated a common inflammatory pathway, or the Toll-like
receptor 4 pathway (Matissek et al., 2021) (Figure 6).
Furthermore, observations revealed a pathway from TLR4 to TRIF and then IRF3 (Matissek et al., 2021). Through
knockout of IRF3, it was found that IRF3 activated the
GLI3 transcription factor (Matissek et al., 2021). When
comparing GLI3 knockout mice to the wild type mice, the
knockout mice had significantly less inflammation
(Matissek et al., 2021). The wild type mice or GLI3
appeared to promote the production of proinflammatory

Figure 6. Activation of GLI3 transcription
via the TLR-4 pathway

cytokines, such as TNF-alpha and IL-6 (Matissek et al., 2021). While a small portion of GLI3’s
mechanisms are understood, its application in inflammation and nociception pain remains
unclear.
Validity of Mouse Models in Studies of Nociception and Inflammation
Mouse models are a beneficial tool that can deepen our understanding of the role of GLI3
in inflammation and nociception. While mouse models are critical to make these discoveries, it is
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important that we recognize what they can and cannot tell us about GLI3’s role in inflammation.
A vital consideration of establishing a model for use, is its validity. Validity is generally taken to
mean confirming the connection between a measurement and what is being measured (F. J. van
der Staay et al., 2009). In the context of animal models, it comprises several distinguishing
factors which can come in many forms (Table 2), that need to be considered individually (F. J.
van der Staay et al., 2009). Structural validity (or construct validity) is used to determine models
based on similarities in mechanisms (Bolker, 2019; F. J. van der Staay et al., 2009). For example,
we can observe nociception in mice because the pathway is the same as in humans (Barrot,
2012). Face validity is based on presumed similarities, for example that mice will react to
noxious stimuli like a human would, based on conservation of pathways (F. J. van der Staay et
al., 2009). In predictive validity models mirror a predicted outcome (F. J. van der Staay et al.,
2009). For example, if GLI3 suppresses inflammation in mice, then it would do the same in
humans because of established structural validity.
Beyond the differing types of validity additional factors are critical to evaluate model use,
such as the historic use of an animal in research. In particular mouse models, were established
early on as a model with strains such as C57BL 6, or “Black 6 mice” with the creation of JAX
laboratories in the 1900’s (Griesemer & Gerson, 2006). Praised for their ability to be genetically
manipulated mice gained substantial recognition as a biomedical model (Griesemer & Gerson,
2006; Åhlgren & Voikar, 2019). The tractability of mouse models has been vital for genetic
manipulation to model desired studies. For example, Black 6 mice have been manipulated to
knockout GLI3 in recent studies that the protein’s role inflammation. This has led to the analysis
of Black 6 mice as a model for studying GLI3’s role in inflammation.
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Black 6 mice are essential animal models to study nociception, inflammation, and GLI3.
Mice hold many structural similarities that make them appropriate models. For example, mice
have many inflammatory molecules that are activated in an immune response that exist in the
human body (Lacy & Stow, 2011). Mice also have a similar pathway of nociception to humans
as the one shown above (Barrot, 2012).). For the purpose of our study the most vital conservation
is the 86% conserved transactivation region between mice and humans. This allows us to make
predications based on GLI3’s ability to activation transcription. Specially our hypothesis is to
elucidate GLI3’s role in inflammation and inflammatory pain.
Form of Validity

Definition

Example

Structural or Construct
Validity

Validity is based on similarities
in underlying mechanisms (i.e.
physical, genetic, behaviorally)
between humans and animal
models (Bolker, 2019; F. J. van
der Staay et al., 2009).
Assessing validity based on
presumed similarities between
an animal model and humans.
Taking the model at face value
alone (F. J. van der Staay et al.,
2009).
The model mirrors what we
predict or expect the outcome
to be in varying targets or
environments. Observations
from the ‘bench’ carry over
similarly to the ‘bedside’ (F. J.
van der Staay et al., 2009).

Mice have an 86% conserved transactivation
region of GLI3 in comparison to human GLI3
(Matissek & Elsawa, 2020)

Face Validity

Predictive Validity

Mice have a similar pathway of nociception
and should act the same as human nociceptive
response (Rostock et al., 2018)

Previous experiments have shown that creinduced mice have inflammation. We predict
that there will be a reduction of inflammation if
we induce cre in our experimental mice
(Elsawa, In Prep).

Table 2. Validity comes in many forms which can be used to warrant the use of an animal model for research.

12

METHODS
Mouse Models
All experiments were carried out with UNH IACUC approval (#210802).
The Jackson lab mice lineage Gli3tm1Alj/J has been backcrossed from 2020 over eleven
generations to create a 99% pure C57BL/6J strain. These mice originate from Gli3tm1Alj /J and
B.6 Cg-Ndor1 Tg(UBC- cre/ERT2)1Ejb / 1J. The mice in this experiment were a result of a parental cross
with GLI3fl/fl- UBC-Cre-ERT2 +/- and GLI3fl/fl -UBC-Cre-ERT2 -/- mice (Figure 7). Therefore,
producing GLI3fl/fl- Ubc-icre -/- (GG++) and GLI3fl/fl Ubc-icre +/- (GGc+) offspring.
Sixty mice were allocated to four treatment groups: GG++ vs GGc+, tamoxifen vs corn
oil, Complete Freund’s adjuvant vs saline, and males vs. females (Table 3). Each mouse
followed a similar experimental timeline (Figure 8). After experimentation was complete, mice
were sacrificed using carbon dioxide for spleen tissue and serum samples.

Non creinduced saline

Non creinduced CFA

Cre-induced
saline
Cre-induced CFA
Table 3. Listing of treatments by genotype and injection composition: non cre-induced saline controls (teal),
non cre-induced CFA (blue), cre-induced saline controls (maroon), and cre-induced CFA (orange).
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Figure 7. The parental cross generated a 50% chance of producing a GLI3fl/fl – UBC-Cre +/mouse or a GLI3fl/fl – UBC-Cre -/- .
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Figure 8. The timeline of experiments began at Day -22 and continued to Day 11, when subjects
were sacrificed.
Genotyping
Mouse DNA was extracted via toe clippings and tail clippings in 0.5 l of DNA release
(Thermo Scientific; F-355) and 19.5l of dilution buffer (Thermo Scientific; 4405587C). The
samples were heated to 98°F on a heat block and stored in a -20F- °C freezer. To prepare the
samples for PCR, a master mix was made with four DNA primers (10-20 micromolar),
EmeraldAmp GT Master Mix(TaKaRa; RR310), and nuclease free water (Table 4). The samples
were then run in a Thermocycler for Polymerase chain reaction (PCR). The PCR denaturation
stage began at 94°C for 1 minute. The annealing stage was run with 35 cycles of 98°C (15 secs),
38.5°C (30 secs), and 72°C (45 seconds). Finally, the extension period ended at 72°C after 7
minutes. The samples were run using 2% gels with SYBR Safe DNA gel stain (Invitrogen;
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S33102) for gel electrophoresis. Samples were run for 30 minutes alongside a GeneRuler 100bp
DNA Ladder (Thermo Scientific; SM0243). These were later evaluated using Image Lab
software (Figure 9).
DNA Primers

298 (sense)
299 (antisense)
418 (sense)
419 (antisense)

Sequence (5’ to 3’)
CTA GGC CAC AGA ATT GAA AGA TCT
GTA GGT GGA AAT TCT AGC ATC ATC C

GAC GTC ACC CGT TCT GTT G
AGG CAA ATT TTG GTG TAC GG

Primer Size

324 base
pairs
(control)
475 base
pairs
(transgene)

Table 4. The primers used to sequence the GLI3 mice.

GLI3fl/fl- UBC-Cre-ERT2 -/(GG++ )

GLI3fl/fl- UBC-Cre-ERT2 +/- (GGc+)

1,000 bp
500 bp
300 bp
100 bp

Figure 9. The genotypes of mice were either Gli3fl/fl – UBC-Cre-ERT +/- , depicted with two bands
or Gli3fl/fl – UBC-Cre-ERT -/-, depicted with one band.
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GLI3 Inducible Knockout Model
GLI3fl/fl -UBC-icre +/- mice were eligible for GLI3 knockout using the Cre-Lox
recombinase method (Figure 10)
(Elsawa, In Prep). The Cre-Lox
recombinase was activated via
intraperitoneal injections of

Exon 8

Tamoxifen (Figure 10) (T5648-1G;
Sigma Aldrich). Tamoxifen binds to
estrogen receptors, which with
repeated exposure knocks out Exon 8,
Figure 10. The Cre/ Lox recombinase knocks out Exon 8, or GLI3
with attachment of Tamoxifen. (Elsawa in Prep)

or GLI3. Tamoxifen was
produced following the

procedure from Jackson Laboratory, by adding 0.02 grams of tamoxifen for every 1 mL of corn
oil (Heffner, 2011). Tamoxifen or corn oil was administered to GLI3fl/fl- Ubc-icre +/- and GLI3fl/fl
Ubc-icre -/- mice via intraperitoneal injections. Injections were administered on alternating sides
of the abdomen for seven days in a row, using a 26-gauge needle and 1mL syringe. Each mouse
received 10 L of either tamoxifen or the vehicle control of corn oil. A rest period of ten days
after injections was allowed for injected mice before experimentation.
Pain Models
Inflammatory Pain Model
The inflammatory pain model was created using Complete Freund’s Adjuvant (CFA)
(F5881; Sigma-Aldrich). CFA injections were formulated using a 1:1 ratio of CFA and saline
(46066-807-25; Aspen) and vortexed to create a uniform suspension. The 50 l CFA injections
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were drawn up using 1mL syringes with 26-gauge safety needles. Using the same measurements,
negative control syringes were generated with saline.
All mice were anesthetized using 2% isoflurane (466066-755-04; Aspen Veterinary
Resources) to minimize pain during injections. The effect of anesthesia was confirmed by
pinching the paw and monitoring movement. Paws were cleaned with Povidone-Iodine prep pads
(1108; Merit Pharmaceuticals) prior to injection. Paws were injected with either CFA or saline
into the hind paw, mid-plantar region. Iodine pads were used to cover the needle after injection
to prevent splash back of biohazardous material. Mice were gently placed into cages and
monitored for movement after the injection and anesthesia. Cages with CFA injected mice were
marked with a biohazard label and observed 24 hours later for paw inflammation.
Paw Examination
Paw width was measured using Mitutoyo electric calipers to note differences preinjection and post-injection. Mice were anesthetized with 2% isoflurane to accurately measure
left and right paw widths (millimeters). Paw widths were compared to measure CFA, or
inflammatory model effectiveness in pre-injected paws versus post-injection paws. These
measurements were also used compared to the saline control paws. In addition to paw width,
mouse weight (grams) was also monitored before and after injections.
Behavior Tests
Hargreaves Plantar Test
The Hargreaves plantar test was the primary method for measuring the thermal
nociceptive responses in mice. A Plantar Test Analgesia Meter machine by IITC Life Science
was set up following the user’s manual (IITC Life Science, 2011). The Hargreaves test is
designed with four major components: the electronic gear, light source, glass frame, and
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plexiglass animal enclosures (Figure 11)(Cheah et al., 2017; IITC Life Science, 2011). The
electronic gear and light source were turned on five to ten minutes to warm up before animal
habituation. The Active Intensity (AI), or percent of maximum heat intensity, was set up to
obtain a baseline response of 9-10 seconds. Based on previous baseline experiments the (AI) of
the bulb was set to 36% of the maximum AI for all experiments. The machine was kept in a
behavioral room with minimal stimuli (Cheah et al., 2017). The room temperature was kept at a

D
C
B

A

Figure 11. Hargreaves Plantar Machine (IITC Life Science, 2011). This includes an A) electronic
gear, B) light source, C) test platform, and D) animal enclosure (Cheah et al., 2017; IITC Life
Science, 2011).
consistent 69-71°F to avoid any differences in behavior. Mice were placed in separate animal
enclosures to acclimate to the behavioral room and movement of the light source. It is worth
noting that the C57BL/6 strain of mice are more active, therefore, habituation roughly occurred
for an hour each trial (Cheah et al., 2017).
The experimenter was blind to genotypes by replacing genotypes with names to avoid
bias. After habituation, the light source was centralized to the hind paw plantar region using a
mirror. Once the timer starts the heat source remains on the paw until a paw withdrawal was
observed (Ning et al., 2022). The paw withdrawal or paw licking must occur deliberately to
prevent voluntary avoidance reactions (Cheah et al., 2017). When the paw is withdrawn, a time
in seconds was obtained for how long the mouse was able to withstand thermal stimuli. The heat
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source had a cut off time of twenty seconds to prevent burns or damage to the paw (Ning et al.,
2022). The mice were tested in five minute intervals and was repeated five times on the left and
right paws (Ning et al., 2022). The pain threshold for each mouse was calculated by taking the
average of the five tests per paw (Cheah et al., 2017). The average pre-injection and postinjection were compared to the baseline measurements of 9-10 seconds.
Von Frey Filament Test
The Von Frey filament test was utilized to observe thermal nociceptive pain response in
mice. The test was set up using a wire mesh platform, animal enclosures, and nylon filaments
(Figure 12) (Sukoff Rizzo, 2014). The Touch Test Sensory nylon filaments (North Coastal
Medical) in this
study followed the
Semmes-Weinstein
Microfilament
protocol with
filament force (in
grams) ranging from
0.008 grams to 4
Figure 12. Mice were raised in enclosures on a mesh platform.
grams (Aesthesio, n.d.).

Similar to the Hargreaves test, the mice were habituated in a behavioral room for at least
one hour, with a temperature of 69-71°F. All subjects start with a 0.4 gram filament to observe
paw withdrawal behavior (Aesthesio, n.d.). The extended filament was pressed into the midplantar region of the hind paw and held for five seconds (Figure 13) (Sukoff Rizzo, 2014). Paw-
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withdrawal, characterized by
movement of paw or licking of the
paw, may occur before the five
seconds are completed (Sukoff Rizzo,
2014). This is considered a response,
whereas no movement indicates non-

Figure 13. The Von Frey filaments are pressed into
the mid-plantar in the hind paw (Sukoff Rizzo, 2014).

response. If the mouse reacted to a
filament, the next filament used will be lower in force. If there was no reaction observed the next
filament would be higher in force. Once again, filaments were tested in five-minute intervals and
were tested at least five times on the left and right paws.

Figure 14. Mice were always first at 0.4 grams of force. Once a change in
response was detected (as depicted from an “X” to and “O”), four more
responses were measured, creating a K sequence of XOXXO for this mouse.
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To calculate the 50% pain threshold of mice, we utilized the Up Down method (Chaplan
et al., 1994). The responses are marked as X’s while the non-responses are marked as O’s. After
the first change in an X O sequence, four more tests are completed (Figure 14). The series of
X’s and O’s provide a unique combination or K value that is interpreted in a list by Chaplan, et al
(Chaplan et al., 1994). The K value is multiplied by the average difference between the log of
fibers(d) and added to the fiber size (Xf).
The variables can be plugged into the following formula:
50% 𝑝𝑎𝑖𝑛 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 =

(10Xf+K∗d )
10,000

Thus, obtaining a 50% pain threshold for a particular mouse and paw. Measurements
were observed before and after paw injections. These were furthermore compared using unpaired
and paired T-tests in Graphpad Prism.
RESULTS
Induction of Cre in GLI3 fl/fl impairs CFA-induced Paw Inflammation
To study how GLI3 might cause inflammation we first had to determine if we had
successfully activated inflammation. This was achieved by studying the left non-injected paws,
or contralateral paws, in comparison to the right injected paws, or ipsilateral paws. The paw
widths (mm) were studied pre-injection on day -2, and post-injection on days 1 and 10.
The ipsilateral paw comparisons were made based on saline injection or CFA injection. By
comparing the two injection types to the contralateral paw with T-tests, we could evaluate if the
pain model was successful. The contralateral paws did not have a significant difference in
comparison to the saline ipsilateral paw widths on day -2 (n =27), 1 (n= 21), or 10 (n= 11 )(P=
0.6477;P= 0.5494;P= 0.8250). The insignificant difference implied that the saline control or the
injection alone, did not affect paw width or inflammation. In contrast paws injected with CFA in
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comparison to contralateral paws did have a significant difference in paw width on day 1 (n= 28)
(P <0.001) and 10 (n= 14) (P <0.001). There was no significance on day -2 (n=33) (P= 0.4582),
suggesting that there was a significant difference in paw width and inflammation when injected
with CFA. Visually the paws injected with CFA were much larger than the contralateral
counterparts, with redness and swelling. In conjunction to the statistical tests, it was evident that
the pain model was activated successfully. CFA generated significant inflammation, while saline
control confirmed an absence of injury because of intraplantar injection.
To assess GLI3’s role in inflammation we studied cre-induced and non cre-induced mice
based on the CFA and saline injections. We expected to see a difference in the inflammation
when cre was induced because GLI3 would not be present to activate protein transcription. We
performed Unpaired and Paired T-tests to observe if the paw width was larger or smaller based
on injection type and cre-induction or non cre-induction. Unpaired T-tests in CFA contralateral
paws for non cre-induced mice (n=16) were not significant between days -2 (P= 0.8443), 1 (P
=0.4493), and 10 (P = 0.8123) in comparison to cre-induce mice (n=17) (Figure 15A). There
was no change in cre-induced and non cre-induced mice in the contralateral paws for CFA mice.
Paired T-tests were compared between days 1 and -2 (P= 0.1329) and days 10 and 1 (P= 0.5471)
for non cre-induced mice. Findings did not show a significant different in contralateral paws for
CFA non cre-induced mice regardless of day. A similar trend was observed for the Paired T-tests
comparing days 1 and -2 (P= 0.4085) and days 10 and 1 (P = 0.4950) for cre-induced mice. As
expected, the cre-induced and non cre-induced contralateral paws were not affected by the CFA
pain model as the injections occurred in only the ipsilateral paws.
In addition, the ipsilateral paws of CFA mice, were compared between cre-induced and
non cre-induced mice (Figure 15B). Unpaired T-tests were tested for between trial day
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(P=0.4656; P= 0.0271; P= 0.338) to compare non cre-induced and cre-induced mice. There was
not a significant difference between days -2 and 10, however there was a significant difference
on day 1. Thus, highlighting the effective nature of the pain model to create inflammation and
cre-induction for creating an acute difference in inflammation. The Paired T-test for both non
cre-induced (P< 0.001) and cre-induced (P<0.001) mice were significant for differences between
day -2 and 1. There were also significant differences for non cre-induced (P= 0.046) and creinduced (P <0.001) mice on day 10 and 1. The significant differences confirmed the differences
in paw widths when mice were injected in the ipsilateral paw with CFA. The CFA injected paws
from cre-induced mice had reduced width and recovered slower to the baseline width compared
with paws from non cre-induced mice. These results suggest that GLI3 could have a role in
healing process of inflammation.
Mice injected with saline were used to confirm that the intraplantar injection had no
effect on paw inflammation. The cre-induced and non-cre-induced mice were once again
compared with T-tests to see if there were differences in the contralateral and ipsilateral paws
regardless of the saline control (Figure 15C, Figure 14D). The saline contralateral paws in the
Unpaired T-tests for non cre-induced mice (n=22) did not have a significant difference in
comparison to cre-induced (n=5) mice on day 1 (P= 0.572) or day 10 (P=0.3711). However,
there was a significant difference on day -2 (P= 0.0168), suggesting a possible difference
between non cre-induced and cre-induced mice paw widths even before saline injection. The
Paired T-tests for non cre-induced mice were not significant between days -1,2, and 10 (P=
0.2159; P= 0.2483). The cre-induced mice did not have a significant difference between paired
T-tests on day -1 and 2 (P= 0.1994) and were inconclusive on day 2 and 10 because of the
reduction in population size. The cre-induction did not appear to effect paw width. Furthermore,
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the saline control was successful, and no differences were detected in paw width due to the
intraplantar injection.

Figure 15. Paw widths of mice were studied by injection type and paws in cre-induced and non cre-induced
mice. CFA injected mice left paws (A) and right paws (B) are compared to saline injected mice left paws (C)
and right paws (D).
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Induction of Cre in GLI3 fl/fl has a mild effect on increasing thermal hypersensitivity
Because inflammation can affect nociceptive response wanted to study if GLI3 had a on
inflammatory pain. In particular we observed thermal nociceptive pain by performing a
Hargreaves plantar test before and after paw injections. The thermal nociceptive response was
studied in contralateral and ipsilateral paws for each injection conditions as well as in creinduced and non cre-induced mice. The contralateral CFA paws were measured using Unpaired
T-tests for non cre-induced and cre-induced mice on days -2 (P= 0.3953), 2 (P= 3536), and 10
(P= 0.3865) (Figure 16A). Each day was not significant implying that there was no difference in
response based on day or cre-induction. Consequently, in Paired T-tests in non cre-induced
(P=0.9801; P= 0.9885) and cre-induced (P=0.9936; 0.4793) mice there was also no significant
difference when comparing day -2 vs 2 and day 10 vs 2. Again, signifying no difference in the
contralateral paws’ time to withdrawal (s) regardless of cre-induction.
A similar approach was used to study the effect of cre-induction on ipsilateral paws in
thermal nociceptive experiments (Figure 16B). The Unpaired T-Tests revealed no significant
difference between cre and non cre-induced mice days 2 and 10 (P= 0.5472; P= 0.2032). There
was no difference in the ipsilateral paw’s withdrawal response based on cre-induced versus non
cre-induced mice. There was, however, a significant difference based on cre-induction on day -2
(P=0.457). These findings could point to a mild difference in initial baselines of nociceptive pain
in cre-induced mice versus non cre-induced mice, but it cannot be truly determined.
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Figure 16. Thermal nociception was measured in cre-induced and non cre-induced mice. Each group was
separated and compared by injection type and paws. CFA injected mice left paws (A) and right paws (B) are
compared to saline injected mice left paws (C) and right paws (D).
Like the paw width experiments, we had to confirm that the saline injection or
intraplantar injection did not affect the thermal nociceptive response. The saline paws for thermal
nociception were also compared in cre and non cre-induced mice. The contralateral and
ipsilateral paws seemed to follow a similar progression overall, because of lack of statistical
significance. The contralateral paws did not show a difference between cre-induced mice and
non cre-induced mice on days -2 (P= 0.3147), 2 (P= 0.4746), or 10 (P= 0.8732) (Figure 16C).
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The ipsilateral paws had a similar pattern with no difference in Unpaired T-tests for day -2 (P=
0.4577), 2 (P= 0.6770), and 10 (P= 0.5631) (Figure 16D). There was no difference in thermal
nociception between saline cre-induced and non-cre induced mice regardless of trial day. The
contralateral paws in non-cre induced mice did not display significance in day -2 versus 2(P=
0.6451), and day 10 versus (P= 0.996); or in right paws on day -2 versus 2 (P= 0.3338). The
saline paws were not affected by thermal nociception based on cre-induction or injected paws.
Induction of Cre in Gli3fl/fl does not influence mechanical allodynia
Because inflammation can affect various nociceptors, we wanted to see if there was any
difference in mechanical nociception based on cre-induction. To measure the mechanical
nociceptive response, we used a Von Frey filament test. We also studied the mechanical
nociceptive response between cre and non cre-induced mice in both paws and injection types.
The CFA contralateral paws did not show differences in mechanical nociception or mechanical
allodynia (Figure 17A). The Unpaired T-test revealed no significant difference between non creinduced and cre-induced contralateral paws on day -1 (P= 0.8946), 3 (P= 0.9400), or 11(P=
0.8899). The Paired T-tests followed the same pattern, with insignificant differences for creinduced mice between days -1 versus 3 (P= P= 0.2492) and 3 versus 11 (P= 0.9761); and with
non cre-induced (P= 0.7352; P= 0.7333). Therefore, implying there was no difference between
CFA contralateral paws for cre-induced and non cre-induced mice’s reaction to mechanical
nociception.
The CFA ipsilateral paw similarly showed no significant difference in reaction to
mechanical stimuli between cre-induced and non cre-induced mice on day -1 (P= 0.1961), 3 (P=
0.6265), and 11 (P= 0.0762) (Figure 17B). The non cre-induced mice did show a significant
difference in Paired T-tests between day -1 and 3 (P=0.0164), implying a change in reaction to
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mechanical stimuli before and after injections with CFA. This was not true for the Paired T-test
between day 3 and 11 (P= 0.4292), which was not significant and had no differences in response
to mechanical stimuli. The cre-induced Paired T-tests revealed no significant differences
between either day -1 and 3 (P= 0.1573) or day 3 and 11 (P= 0.7289). The cre-induction did not
appear to be affected by mechanical stimuli or injection type.
The saline contralateral and ipsilateral paws were also compared between cre-induced
and non cre-induced mice. This was once again to confirm that the injection did not affect

Figure 17. Mechanical nociception was measured in cre-induced and non cre-induced mice. Each group was
separated and compared by injection type and paws. CFA injected mice left paws (A) and right paws (B) are
compared to saline injected mice left paws (C) and right paws (D).
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inflammation or the mechanical nociceptive response. The contralateral paws did not show a
significant difference based on cre-induction on days -1 (P= 0.1644), 3 (P= 0.5824), and 11 (P=
0.7985) (Figure 17C). The Unpaired T-tests repeated for the ipsilateral paw on days -1 (P=
0.9788), 3 (P= 0.1160), and 11 (P= 0.5415), were also not significant (Figure 17D). This implied
that there was no difference in reaction to mechanical stimuli in saline injected mice, regardless
of cre-induction. The lack of significance was highlighted once again in Paired T-tests for
contralateral and ipsilateral paws. Non cre-induced mice with right paws showed no difference
between days -1 and 3 (P=0.1395) as well as day 3 and 11 (P= 0.7560). Cre-induced mice were
also not significant between days -1 and 3 (P=0.3079). There were not enough pairs to determine
if cre-induced mice had similarities or differences in their reaction to mechanical stimuli on days
3 versus 11 for left and right paws. The ipsilateral paws did not differ from contralateral paws
and did not have significant differences in non cre-induced mice between days -1 and 3
(P=0.1518) or day 3 and 11 (0.7679). Finally, cre-induced mice were not significant in Paired Ttests comparing day -1 and 3 (P=0.5586). Overall, the contralateral and ipsilateral paws did not
have a reaction to mechanical stimuli based on cre-induction or injection.
DISCUSSION
Pain Model Efficacy
The inflammatory pain model in mice was represented by intraplantar injections of CFA.
To control for the intraplantar injection or potential paw injury, saline was injected into right
paws. By comparing the contralateral and ipsilateral paw widths before and after injections we
were able to determine if inflammation was successfully induced. The CFA was successful at
causing an increase in paw widths after injections, implying that inflammation was potentially
induced. Without analysis of inflammatory molecules, we cannot be certain this was
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inflammation. In contrast the saline paws before and after injection had no difference in paw
widths, confirming that no injury took place due to injections. This also assured that the needle
or injection did not cause an inflammatory response within the paw.
CFA acted as a beneficial model of chronic inflammation. The mouse models acted as an
important proxy to human inflammation due to similarities in the immune response (van der
Staay et al., 2009). The murine immune system contains similar chemokines and cytokines such
as IL-6 and TNF- that occur in an inflammatory response (Schinnerling et al., 2019). On the
other hand, the murine immune system continues to have some differences in immune reaction.
For example, Th17 cells dominate the inflammatory immune response in mouse models, whereas
humans' immune response uses a diverse range of Th1, Th17, and Th1/17 cells that also play
apart outside of the normal innate immune cells (Schinnerling et al., 2019). Additionally, chronic
inflammatory diseases in humans have diverse characteristics and it would be false to assume the
CFA encompasses that variation.
GLI3 is likely to play a role in inflammation
We used paw widths as a method to observe inflammation and the effect of cre-induction
on the scale of inflammation. The paw widths were measured and assessed between cre-induced
and non cre-induced mice. The contralateral paws CFA injected mice did not have a difference in
inflammation regardless of cre-induction. However, CFA mice injected in the ipsilateral paw did
show a difference in initial or acute inflammation between cre-induced and non cre-induced
mice. Therefore, insinuating that cre-induction influenced the paw width or maybe inflammation.
There was no difference in 10 days post-injection which could allude to cre-induction only
having an effect in the first few stages of inflammation, but not chronic inflammation. The saline
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mice only had differences on day -1, which implied that cre-induction could have a difference on
paw width regardless of injection.
Once again, it is critical to acknowledge the implications from using a mouse model. As
described in the pain model section, murine immune systems hold many similarities and
differences to the human inflammatory response. Mice act as appropriate models for creinduction with an 86 % conserved region of GLI3’s transactivation site (Matissek & Elsawa,
2020). Because much of GLI3’s role is unknown we cannot determine if the remaining 14% is
critical for assessing GLI3’s function.
Thermal hypersensitivity is mildly affected by cre-induction of GLI3fl/fl
Thermal hypersensitivity was studied by observing withdrawal responses in contralateral
and ipsilateral paws before and after injections. In particular we hoped to observe a difference
between cre-induced and non cre-induced mice. Similar to the saline paw widths only the
baseline measurements of thermal nociception were different for CFA right paw, which
highlighted a difference in beginning between cre-induced and non cre-induced mice. There
were no significant differences between any other injection types or days between cre-induced
and non cre-induced mice.
Because there is a conservation of the nociceptive pathway between mice and humans it
would be anticipated that these results would be an accurate indicator of human nociceptive
response to thermal stimuli (Barrot, 2012). We must recognize, that there still appears to be
differences in the human and mouse nociceptors, which may affect nociceptor function. For
example, studies have revealed that nociceptors involved in heat and inflammation are more
prevalent in humans than in mice (Rostock et al., 2018). It can also be tricky to compare thermal
nociceptive tests in a controlled setting to the exposure of numerous noxious stimuli in everyday
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life. Detecting nociception in mice seems straight forward, but we could not truly assess the
umwelt of the mice’s capacity to feel pain, nociceptive pain, neither or both.
Gli3fl/fl Does not Affect Mechanical Nociception Response
The mechanical nociception response in cre-induced and non cre-induced mice was
observed using the Von Frey filament test. The reactions were studied before and after injections
with CFA and or saline. The statistical tests did not reveal significant differences based on paw,
injection type, or cre-induction. However, on day 11 of ipsilateral CFA paws, the cre-induced
mice did not appear to recover. This could point to GLI3 as an important mediator of acute
inflammation and healing. Because of the lack of significance, this is only based on speculation.
It does not appear that GLI3 affected mechanical nociceptive response.
Like the thermal nociception, it is beneficial that there is some conservation between
human and mice pathways of nociception. There are similar nociceptors, such as C-fibers that
interpret mechanical nociception, yet the interaction between these nociceptors and GLI3
remains unknown (Rostock et al., 2018).
GLI3 is not Involved in Nociceptive pain
While GLI3 appears to have a role inflammation or potentially acute pain, it is possible
that GLI3 does not play a role in nociceptive pain. Previous studies have observed GLI3 through
the means of atopic dermatitis (Matissek & Elsawa, 2020). In comparison to our experimental
design, we induced inflammation on the inside of the mouse instead of on top of the skin. It is
possible that to begin with there is a difference in immune response, and or even inflammatory
molecules. This can be confirmed by studying serum samples of the experimental mice. The
behavioral tests revealed that cre-induced mice did not have major or apparent differences in the
mechanical or thermal nociceptive response. In contrast the paw widths did show a difference in
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inflammation between cre-induced and non cre-induced mice. This insinuates that GLI3 may
play an important role in inflammation, but not pain, or at the least not nociceptive pain.
Future Directions
While inflammation via CFA apparent in mouse models, further studies should confirm
what immune modulators were activated in response to CFA from serum samples. The samples
should also be compared to saline or control samples to establish a baseline of circulating
immune molecules. As distinguished by our study however, using paw widths appears to be an
appropriate method to monitor inflammation.
Moving forward in paw width studies, the GLI3 knockout should be first confirmed with
Western blots. The Western blot can be used to compare harvested organ tissues from creinduced and non cre-induced mice for the presences of GLI3. The bands should show the
absence of the GLI3 protein in the cre-induced mice Essentially, the Western blot should confirm
if the inducible knockout model or cre-induction was successful. There are a variety of methods
to identify the GLI3 protein, such as immunohistochemistry staining, yet Western blots are the
most efficient.
Studies with serum samples should also be performed to observe differences in GLI3
knockout mice or non GLI3 knockout mice. By drawing comparisons to findings by Elsawa and
Matissek, 2020, serum samples could reveal if GL3 played a role in activating inflammation. For
example, by looking closely at pro-inflammatory cytokines such as IL-6. It is also important to
understand if these inflammatory molecules are interacting or causing differences in nociceptive
responses.
Future experiments using mouse models could be improved by experimenting with
additional noxious stimuli, such as with cold temperatures instead of heat. Based on our findings
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it does not appear the cre-induced mice had a difference in their response to thermal or
mechanical nociception. Therefore, it would be beneficial to again observe serum samples for
any inflammatory molecules that may or may not interact with nociceptors. It is plausible that
GLI3 has a prominent role in inflammation or the healing stages of inflammation rather than pain
or nociception. With the novel role of GLI3 in mouse model inflammation there is ample
opportunity to discover its true role in acute inflammation and pain.
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